VITAL Findings — A Decisive Verdict on Vitamin D Supplementation

This editorial summarizes findings from the Vitamin D and Omega 3 Trial (VITAL) and its ancillary study, which evaluated the effects of vitamin D₃ supplementation (2000 IU/day) on health outcomes in older adults. The study, involving 25,871 participants, found no significant benefits of vitamin D supplementation in preventing fractures, cancer, cardiovascular disease, or other conditions even in subgroups with low baseline 25 hydroxyvitamin D levels. The authors conclude that routine screening for vitamin D levels and widespread supplementation are unjustified for the general population, though targeted use may remain relevant for specific high risk groups (e.g., those with severe deficiency or malabsorption). The results challenge common clinical practices and redefine the understanding of vitamin D's role in public health.

This editorial summarizes findings from the Vitamin D and Omega 3 Trial (VITAL) and its ancillary study, which evaluated the effects of vitamin D₃ supplementation (2000 IU/day) on health outcomes in older adults. The study, involving 25,871 participants, found no significant benefits of vitamin D supplementation in preventing fractures, cancer, cardiovascular disease, or other conditions even in subgroups with low baseline 25 hydroxyvitamin D levels. The authors conclude that routine screening for vitamin D levels and widespread supplementation are unjustified for the general population, though targeted use may remain relevant for specific high risk groups (e.g., those with severe deficiency or malabsorption). The results challenge common clinical practices and redefine the understanding of vitamin D's role in public health.